Astellas Pharma has teamed up with Mitsubishi Research Institute (MRI) to support drug-discovery startups in Japan, aiming to enhance their global presence.

This partnership is designed to provide Japanese drug startups with valuable insights into the pharmaceutical industry, thereby improving their chances for international growth and licensing.

The collaboration seeks to bolster Japan's position in drug research and assist emerging companies in achieving international success.

MRI will utilize its extensive experience from the MEDISO program, which has supported over 1,200 startups and research groups, to create customized support plans for the participating startups.

Tadaaki Taniguchi, Astellas' chief R&D officer, highlighted the company's dedication to fostering innovative ideas and technologies through partnerships with academia and startups.

The initiative is backed by Japan's Ministry of Health, Labour and Welfare through the Medical Innovation Support Office (MEDISO), which aims to enhance the practical applications of Japan's life sciences technology.

This project aligns with Japan's Basic Policy on Economic and Fiscal Management and Reform 2024, which emphasizes improving research environments and attracting global investment.

Hirofumi Suzuki from MRI stressed the importance for drug-discovery startups to gain external insights and expertise to expedite their commercialization efforts.

Astellas will offer participating startups access to laboratory and office space at its SakuLab™-Tsukuba facility, along with consultations from its experts.

At SakuLab™-Tsukuba, startups will benefit from guidance by Astellas experts and collaboration opportunities with other researchers and startups, which will help accelerate their drug development processes.